Medtronic’s Hugo surgical robot features a modular design that allows surgeons to use only the robotic arms needed for any given procedure. | Source: Medtronic
Medtronic this week announced the U.S. Food and Drug Administration (FDA) has cleared the Hugo robotic-assisted surgery system for use in general surgery procedures. The approval enables the modular, cart-based system to perform surgeries across the abdomen.
The clearance covers all upper abdominal general surgical procedures, including cholecystectomy, Roux-en-Y gastric bypass, ventral hernia, and small bowel resection. The FDA also cleared lower abdominal procedures of inguinal hernia and appendectomy.
Combined, Medtronic said these procedures account for about 3.5 million surgeries annually in the U.S.
“We started our U.S. journey in February of last year,” Rajit Kamal, the general manager of robotic surgical technologies at Medtronic, told The Robot Report. “We have been pleased with the progress we have made. We are in many leading hospitals in the country with our urology indication. Our general surgery further opens those opportunities for us and for our combined value proposition, not just for Hugo, but in service, training, support, touch surgery, and the broader portfolio.”
Medtronic already has experience in many of these general surgery areas. The company said its technologies in open and laparoscopic approaches have been used for more than fifty years.
Medtronic received CE marking for general surgery in Europe in 2022. S. submission. Globally, Hugo is on track to surpass 50,000 cumulative procedures by the end of the Medtronic fiscal year.
Source link







